STAT3-Luc/EF1α-mCherry Reporter Cell Line - HeLa

STAT3-Luc/EF1α-mCherry Reporter Cell Line - HeLa is a dual-reporter human cervical cancer cell line engineered for sensitive monitoring of signal transducer and activator of transcription 3 (STAT3) pathway activity. The cells stably express firefly luciferase under the control of a STAT3-responsive promoter, enabling quantitative measurement of STAT3-dependent transcriptional activation through luminescence detection. In parallel, mCherry is constitutively expressed from the EF1α promoter and serves as a robust fluorescent marker for cell identification, viability assessment, normalization, and visualization of cell growth. Built on the widely used HeLa background, this reporter cell line combines the high transfection compatibility and reproducible growth characteristics of HeLa cells with a convenient, non-destructive readout of STAT3 signaling. The dual-reporter design supports both plate-reader-based luciferase assays and fluorescence-based imaging or flow cytometry workflows, providing a reliable tool for studies of cytokine- and growth factor-mediated STAT3 activation.

This cell line is suitable for screening and characterization of STAT3 agonists, inhibitors, degraders, neutralizing antibodies, and pathway-modulating biologics. It can be used to evaluate responses to IL-6 family cytokines, JAK/STAT-targeted compounds, receptor ligands, and tumor microenvironment-associated factors that influence STAT3 transcriptional activity. In drug discovery, the luciferase signal enables scalable quantitative screening in multiwell formats, while constitutive mCherry fluorescence helps monitor cell number, transduction efficiency, and assay consistency. The model is also valuable for mechanistic studies of upstream JAK kinases, cytokine receptors, phosphatases, and cross-talk between STAT3 and other signaling networks, including MAPK, PI3K/AKT, and NF-κB pathways. In addition, it can support dose-response analysis, time-course studies, combination-treatment evaluation, and functional validation of gene-editing or RNA interference experiments targeting components of the STAT3 pathway.